Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Qiagen (QGEN – Research Report), Roche Holding AG (RHHVF – Research Report) and Crossject SA (CRJTF – Research Report).
Deutsche Bank analyst Falko Friedrichs maintained a Buy rating on Qiagen yesterday. The company’s shares closed last Thursday at $46.77.
According to TipRanks.com, Friedrichs is ranked #1993 out of 7550 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qiagen with a $60.36 average price target, representing a 28.9% upside. In a report issued on June 8, Goldman Sachs also maintained a Buy rating on the stock.
Roche Holding AG (RHHVF)
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Roche Holding AG yesterday and set a price target of CHF325.00. The company’s shares closed last Thursday at $376.00, close to its 52-week high of $388.50.
According to TipRanks.com, Papadakis is a 2-star analyst with an average return of 0.9% and a 52.3% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Grifols SA, and Galapagos.
The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $382.65 average price target, which is a 0.4% upside from current levels. In a report issued on June 2, Societe Generale also downgraded the stock to Hold with a CHF340.00 price target.
Crossject SA (CRJTF)
Kepler Capital analyst Paul de Froment maintained a Hold rating on Crossject SA on June 16 and set a price target of EUR3.60. The company’s shares closed last Tuesday at $3.25, equals to its 52-week low of $3.25.
According to TipRanks.com, Froment is ranked #2443 out of 7550 analysts.
Currently, the analyst consensus on Crossject SA is a Hold with an average price target of $4.29.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.